31.34
0.08 (0.26%)
| Previous Close | 31.26 |
| Open | 31.17 |
| Volume | 296,259 |
| Avg. Volume (3M) | 1,960,673 |
| Market Cap | 5,173,543,936 |
| Price / Earnings (TTM) | 15.14 |
| Price / Earnings (Forward) | 18.62 |
| Price / Sales | 3.48 |
| Price / Book | 3.18 |
| 52 Weeks Range | |
| Earnings Date | 23 Oct 2025 |
| Profit Margin | 23.30% |
| Operating Margin (TTM) | 4.50% |
| Diluted EPS (TTM) | 2.10 |
| Quarterly Revenue Growth (YOY) | -12.50% |
| Quarterly Earnings Growth (YOY) | -39.00% |
| Total Debt/Equity (MRQ) | 4.90% |
| Current Ratio (MRQ) | 3.33 |
| Operating Cash Flow (TTM) | 516.83 M |
| Levered Free Cash Flow (TTM) | 429.53 M |
| Return on Assets (TTM) | 11.62% |
| Return on Equity (TTM) | 25.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Bullish | |
| Stock | Alkermes plc | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | -1.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.40 |
|
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Insiders | 1.49% |
| % Held by Institutions | 107.53% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 46.00 (HC Wainwright & Co., 46.78%) | Hold |
| Median | 44.00 (40.40%) | |
| Low | 35.00 (JP Morgan, 11.68%) | Hold |
| Average | 42.80 (36.57%) | |
| Total | 3 Buy, 2 Hold | |
| Avg. Price @ Call | 28.12 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 26 Sep 2025 | 44.00 (40.40%) | Buy | 27.89 |
| 30 Jul 2025 | 42.00 (34.01%) | Hold | 27.93 | |
| HC Wainwright & Co. | 09 Sep 2025 | 46.00 (46.78%) | Hold | 27.85 |
| 21 Jul 2025 | 46.00 (46.78%) | Hold | 26.66 | |
| JP Morgan | 09 Sep 2025 | 35.00 (11.68%) | Hold | 27.85 |
| Wells Fargo | 03 Sep 2025 | 44.00 (40.40%) | Buy | 30.00 |
| Needham | 29 Jul 2025 | 45.00 (43.59%) | Buy | 27.00 |
| 21 Jul 2025 | 45.00 (43.59%) | Buy | 26.66 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HOPKINSON CRAIG C. | - | 32.23 | -9,000 | -290,070 |
| Aggregate Net Quantity | -9,000 | |||
| Aggregate Net Value ($) | -290,070 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 32.23 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HOPKINSON CRAIG C. | Officer | 15 Oct 2025 | Automatic sell (-) | 9,000 | 32.23 | 290,070 |
| HOPKINSON CRAIG C. | Officer | 15 Oct 2025 | Option execute | 5,000 | - | - |
| Date | Type | Details |
|---|---|---|
| 12 Sep 2025 | Announcement | Alkermes Appoints Joshua Reed as Chief Financial Officer |
| 11 Sep 2025 | Announcement | Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program |
| 08 Sep 2025 | Announcement | Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025 |
| 25 Aug 2025 | Announcement | Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025 |
| 29 Jul 2025 | Announcement | Alkermes plc Reports Second Quarter 2025 Financial Results |
| 21 Jul 2025 | Announcement | Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |